4-hydroxy-1-glycolylpiperidine | 929874-82-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-hydroxy-1-glycolylpiperidine
• 英文别名: 2-Hydroxy-1-(4-hydroxy-1-piperidyl)ethanone；2-hydroxy-1-(4-hydroxypiperidin-1-yl)ethanone
• CAS: 929874-82-8
• 化学式: C₇H₁₃NO₃
• 分子量: 159.185
• InChiKey: OESLFMGEBKPAHH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.1
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  60.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-羟基哌啶 、 2,2-二甲基-1,3-二氧戊环-4-酮 以 二氯甲烷 为溶剂， 以20%的产率得到4-hydroxy-1-glycolylpiperidine
  参考文献：
  名称：

  Synthesis and evaluation of in vitro anti-tuberculosis activity of N-substituted glycolamides

  摘要：

  On the basis of the structural similarity of N-substituted glycolamides with N-glycolyl muramic acid residues of the cell wall of Mycobacterium tuberculosis, a series of these compounds were designed and synthesized by the reaction of glycolic acid acetonide 1 (2,2-dimethyl-5-oxo-1,3-dioxolane) with the proper amines. The minimum inhibitory concentration (MIC) was determined against M. tuberculosis H(37)Rv in BACTEC 12B medium, using the Microplate Alamar Blue Assay (MABA). Among the synthesized compounds, all those with disubstituted amide structure accompanied by one or two heteroatom(s) with loan pair(s) of electrons atom(s) P to the amide nitrogen demonstrated moderate anti-tuberculosis activity and all the monosubstituted amides showed no activity at all. (C) 2008 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2008.02.022

文献信息

• [EN] TANK-BINDING KINASE INHIBITOR COMPOUNDS<br/>[FR] COMPOSÉS INHIBITEURS DE KINASES SE LIANT À TANK
  申请人：GILEAD SCIENCES INC

  公开号：WO2015187684A1

  公开（公告）日：2015-12-10

  Compounds having the following formula (I) and methods of their use and preparation are disclosed:

  揭示了具有以下化学式（I）的化合物及其使用和制备方法。
• [EN] METHODS OF TREATING ALZHEIMER'S DISEASE USING AROMATICALLY SUBSTITUTED omega-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES<br/>[FR] METHODES DE TRAITEMENT DE LA MALADIE D'ALZHEIMER AU MOYEN D'AMIDES D'ACIDE O-AMINO-ALCANOIQUE A SUBSTITUTIONS AROMATIQUES ET DE DIAMIDES D'ACIDE ALCANOIQUE
  申请人：ELAN PHARM INC

  公开号：WO2003103652A1

  公开（公告）日：2003-12-18

  Disclosed.are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting deposition of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R1, R2, R3, R4, R5, X1, and X2 are defined herein.

  披露了治疗阿尔茨海默病和其他疾病，和/或抑制β-分泌酶酶，和/或通过使用式(I)化合物在哺乳动物体内抑制Aβ肽沉积的方法，其中变量R1、R2、R3、R4、R5、X1和X2在此处定义。
• Fused-ring compounds and use thereof as drugs
  申请人：Japan Tobacco Inc.

  公开号：US20030050320A1

  公开（公告）日：2003-03-13

  The present invention provides a fused ring compound of the following formula [I] 1 wherein each symbol is as defined in the specification, a pharmaceutically acceptable salt thereof, and a therapeutic agent for hepatitis C, which contains this compound. The compound of the present invention shows an anti-hapatitis C virus (HCV) action based on the HCV polymerase inhibitory activity, and is useful as a therapeutic agent or prophylactic agent for hepatitis C.

  本发明提供了以下式子的融合环化合物I1，其中每个符号如规范所定义，其药用盐，以及包含该化合物的治疗丙型肝炎的治疗剂。本发明的化合物显示出基于HCV聚合酶抑制活性的抗丙型肝炎病毒（HCV）作用，并且可用作治疗或预防丙型肝炎的药物。
• Fluorene Compound and Pharmaceutical Use Thereof
  申请人：Motomura Takahisa

  公开号：US20100240634A1

  公开（公告）日：2010-09-23

  The present invention provides an agent for the prophylactic or treatment of diabetes, diabetic complications, insulin resistance syndrome, metabolic syndrome, hyperglycemia, dyslipidemia, atherosclerosis, cardiac failure, cardiomyopathy, myocardial ischemia, brain ischemia, cerebral apoplexy, pulmonary hypertension, hyperlactacidemia, mitochondrial disease, mitochondrial encephalomyopathy or cancer, namely, a PDHK inhibitor and the like. A compound represented by the following formula [I] or a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein each symbol is as defined in the specification.

  本发明提供了一种用于预防或治疗糖尿病、糖尿病并发症、胰岛素抵抗综合征、代谢综合征、高血糖、血脂异常、动脉粥样硬化、心力衰竭、心肌病、心肌缺血、脑缺血、脑卒中、肺动脉高压、高乳酸血症、线粒体疾病、线粒体脑病或癌症的药剂，即PDHK抑制剂等。一种由下式[I]表示的化合物或其药学上可接受的盐，或其溶剂：其中每个符号如规范中所定义。
• Methods of treating alzheimer's disease using aromatically substituted w-amino-alkanoic acid amides and alkanoic acid diamides
  申请人：Maillard Michel

  公开号：US20060089355A1

  公开（公告）日：2006-04-27

  Disclosed are methods for treating Alzheimer's disease, and other diseases, and/or inhibiting beta-secretase enzyme, and/or inhibiting de-position of A beta peptide in a mammal, by use of compounds of formula (I) wherein the variables R 1 , R 2 , R 3 , R 4 , R 5 , X 1 , and X 2 are defined herein.

  本发明涉及使用式(I)中的化合物治疗阿尔茨海默病和其他疾病，抑制β-秘鲁酶的活性，抑制Aβ肽在哺乳动物体内的沉积。其中，变量R1、R2、R3、R4、R5、X1和X2的定义如下。